Influence of Dopaminergic Blockade on Stress Responses, Motivation and Emotional Reactivity in Humans.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

85 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-15

Study Completion Date

2020-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to identify whether partial blockade of human dopamine signaling with antipsychotic drugs affects human stress responses, motivation and emotion. 84 healthy adult participants are planned to complete the study protocol.

Therefore three experiments are planned:

Experiment 1: Influence of amisulpride on human stress responses. Experiment 2: Influence of amisulpride on motivated effort. Experiment 3: Influence of amisulpride on emotion.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Examining the Effects of Antipsychotic Medications on Insulin Sensitivity

NCT00895921

Diabetes

COMPLETED PHASE4

Molecular Mechanisms of Antipsychotic-induced Insulin Resistance

NCT02708394

Adverse Effect of Other Antipsychotics and Neuroleptics Insulin Resistance

COMPLETED EARLY_PHASE1

Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism

NCT01160991

Schizophrenia Diabetes Insulin Resistance

COMPLETED NA

Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders

NCT03943537

Psychosis Schizophrenia Schizo Affective Disorder +1 more

COMPLETED PHASE2

One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome

NCT00748566

Schizophrenia and Disorders With Psychotic Features

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is a double blind, placebo controlled, randomized trial with two groups. One group will be receiving placebo (PG) and the other group will receive 300 mg amisulpride (VG). All participants are planned to complete all three experiments sequentially after drug/placebo intake.

In experiment 1 we want to test whether a medium single dosage of amisulpride (VG) changes human stress responses compared to the PG. Therefore test subjects take the medication / placebo and wait for peak plasma levels. Afterwards they undergo a standardized stress test (MAST procedure,e.g. Shilton et al., 2017) where they submerge their non-dominant hand in cold water and have to do mental arithmetic tasks. We collect ECG, cortisol and skin conductance data as well as subjective measures of the stress response.

In experiment 2 that is done after completion of experiment 1 the aim is testing whether the VG compared to the PG has an altered motivated effort. Therefore so called effort based paradigms (Reddy et al., 2015) are used. In these paradigms participants are given the option between an easy and effortless way of solving a trial that is reinforced with a small monetary reward or a harder and effortful way of trial solving that is rewarded higher. We measure how often the VG versus the PG will take the easy, low reward option over the hard, high reward option.

In experiment 3 and after the completion of experiment to the aim is it to test whether the mean intensity of visually evoked emotions in the VG is changed compared to the PG. Therefore we use a stimulus set (15 positive images, 15 negative images, 15 neutral images) out of the International Affective Picture System images to evoke emotions and plan to analyze data like in positivity offset research (detailed description in: Strauss et al, 2017).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Participants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

randomized, double blind, placebo controlled, between subjects design

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

amisulpride group

300 mg of the atypical antipsychotic drug amisulpride

Group Type ACTIVE_COMPARATOR

Amisulpride 300 MG

Intervention Type DRUG

A single dose of 300 mg amisulpride that looks identical to placebo control capsules.

placebo group

Similar looking capsules for placebo control

Group Type PLACEBO_COMPARATOR

Placebo oral capsule

Intervention Type DRUG

A placebo capsule with no inert pharmacological effect. Looks identical to the amisulpride capsules.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amisulpride 300 MG

A single dose of 300 mg amisulpride that looks identical to placebo control capsules.

Intervention Type DRUG

Placebo oral capsule

A placebo capsule with no inert pharmacological effect. Looks identical to the amisulpride capsules.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Common European Framework of Reference for Languages level B2 in German language.
* Consent ability for all relevant aspects of the experiment.

Exclusion Criteria

* Amisulpride allergy.
* Allergy to other components of amisulpride / placebo capsules like lactose.
* Daily intake of other medication including contraceptives.
* Tendency to seizures.
* Diagnosis of cancer especially pheochromocytoma, prolactinoma, or breast cancer.
* Kidney dysfunction: creatinine clearance below 10 ml per minute.
* High risk for stroke or thrombosis.
* Known prolongation of the QT interval,
* Any substantial medical condition that is capable of reducing the volunteers ability to participate at the study.
* Suicidal thoughts or suicide attempts in the past or at present.
* Substantial mental disorders especially schizophrenia, bipolar disorder, drug abuse, or personality disorders.
* Pregnancy or breastfeeding.

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes